It is common for Escherichia coli to cause urinary tract infections (UTIs). These isolates have been recognized to be increasingly resistant to fluoroquinolones and sulfamethoxazole trimethoprim. SMX-TMP and fluoroquinolones both appear to have limited stack factors for resilience. Objectives: Sulfamethoxazole - trimethoprim and levofloxacin resistance among Escherichia coli separate discharged from the crisis department was evaluated in this study. A contemplative review was conducted of adults discharged from the ED with Escherichia coli UTIs. Our study investigated the presence of Escherichia coli noncompliance to Sulfamethoxazole - trimethoprim and fluoroquinolones and the risk factors associated with these infections by incorporating demographic and clinical data. A mean rate of 79.8% and 69.4% of 240 patients were open to antibiotics or Sulfamethoxazole - trimethoprim, respectively. Previous antibiotic use (p=0.05) and a history of UTIs (p=0.02) showed notable risks of resistance to SMX-TMP. It was found that age, male gender, hypertension, diabetes, chronic respiratory disease, nursing home residents, prior antibiotic use, a previous diagnosis of UTI, renal or genitourinary abnormalities, and prior surgical procedures were significant risk factors for resistance to levofloxacin. Hospital days prior to ED evaluation were found to predict hospital and ED readmissions (p=0.001). Conventional methods of monitoring susceptibility patterns may not be adequate based on these results. To identify patients at risk of resistance, practitioners need to develop novel approaches. In comparison to uncomplicated UTIs presented in the ED with risk factors identified from this evaluation, providers should consider scrutinizing their use of these agents